Chimeric Antigen Receptor T (CAR-T) Cells Market Report 2023 | Market Size, Trends, And Market Forecast 2023-2032 | Novartis International AG, Pfizer Inc., Gilead Sciences Inc., Autolus Therapeutics Plc, CARsgen Therapeutics Company Limited

Chimeric Antigen Receptor T (CAR-T) Cells Market Size
Spread the love

The Business Research Company’s Chimeric Antigen Receptor T (CAR-T) Cells Global Market Report 2023 is the most detailed report available on the market, including broad forecast periods and multiple geographies. The report covers the historic period – 2010-2021, and the forecast period – 2023-2032. The Chimeric Antigen Receptor T (CAR-T) Cells Global Market Report 2023 evaluates chimeric antigen receptor T (CAR-T) cells market size, growth rate, drivers, trends, and major companies.

The report provides a global perspective by covering 60 geographies and focusing on major economies in each region – Asia-Pacific, Western Europe, Eastern Europe, North America, South America, Middle East, Africa.

Request A Free Sample Of The Report (Includes Graphs And Tables):
https://www.thebusinessresearchcompany.com/sample.aspx?id=8124&type=smp

The global chimeric antigen receptor T (CAR-T) cells market size is expected to grow from $1.96 billion in 2022 to $2.76 billion in 2023 at a compound annual growth rate (CAGR) of 40.9%. The Russia-Ukraine war disrupted the chances of global economic recovery from the COVID-19 pandemic, at least in the short term. The war between these two countries has led to economic sanctions on multiple countries, a surge in commodity prices, and supply chain disruptions, causing inflation across goods and services and affecting many markets across the globe. The chimeric antigen receptor T (CAR-T) cells market size is expected to grow to $10.24 billion in 2027 at a CAGR of 38.8%.

The Chimeric Antigen Receptor T (CAR-T) Cells Market Segments In The Report Are:

Chimeric Antigen Receptor T (CAR-T) Cells By Target Antigen:
CD19
CD22
Other Antigens

Chimeric Antigen Receptor T (CAR-T) Cells By Application:
Acute Lymphoblastic Leukemia
Diffuse Large B-Cell Lymphoma
Other Applications

Chimeric Antigen Receptor T (CAR-T) Cells By End User:
Hospitals
Cancer Research Centres
Clinics

Top Key Players:

Novartis International AG
Pfizer Inc.
Gilead Sciences Inc.
Autolus Therapeutics Plc
CARsgen Therapeutics Company Limited

North America was the largest region in the chimeric antigen receptor T (CAR-T) cells market in 2022.

Get More Information On The Chimeric Antigen Receptor T (CAR-T) Cells Market Report:

https://www.thebusinessresearchcompany.com/report/chimeric-antigen-receptor-t-car-t-cells-global-market-report

The table of contents in TBRC’s chimeric antigen receptor T (CAR-T) cells market report includes:

1. Executive Summary
2. Chimeric Antigen Receptor T (CAR-T) Cells Market Characteristics
3. Chimeric Antigen Receptor T (CAR-T) Cells Market Trends And Strategies
4. Chimeric Antigen Receptor T (CAR-T) Cells Market – Macro Economic Scenario
5. Chimeric Antigen Receptor T (CAR-T) Cells Market Size And Growth
…..
26. Africa Chimeric Antigen Receptor T (CAR-T) Cells Market
27. Chimeric Antigen Receptor T (CAR-T) Cells Market Competitive Landscape And Company Profiles
28. Key Mergers And Acquisitions In The Chimeric Antigen Receptor T (CAR-T) Cells Market
29. Chimeric Antigen Receptor T (CAR-T) Cells Market Future Outlook and Potential Analysis
30. Appendix

List Of Tables

Table 1: Global Historic Market Growth, 2017-2022, $ Billion

Table 2: Global Forecast Market Growth, 2022-2027F, 2032F, $ Billion

Table 3: Global Chimeric Antigen Receptor T (CAR-T) Cells Market, Segmentation By Target Antigen, Historic and Forecast, 2017-2022, 2022-2027F, 2032F, $ Billion

Table 4: Global Chimeric Antigen Receptor T (CAR-T) Cells Market, Segmentation By Application, Historic and Forecast, 2017-2022, 2022-2027F, 2032F, $ Billion

Table 5: Global Chimeric Antigen Receptor T (CAR-T) Cells Market, Segmentation By End User, Historic and Forecast, 2017-2022, 2022-2027F, 2032F, $ Billion
…..
Table 46: Novartis International AG Financial Performance

Table 47: Pfizer Inc Financial Performance

Table 48: Gilead Sciences Inc Financial Performance

Table 49: Autolus Therapeutics Plc Financial Performance

Table 50: CARsgen Therapeutics Company Limited Financial Performance

Read Related Reports:
https://www.openpr.com/news/3035831/aspirin-market-outlook-size-share-industry-trends-report

https://www.openpr.com/news/3035843/2023-global-eylea-market-size-share-growth-trends

https://www.openpr.com/news/3035867/gene-expression-market-size-growth-drivers-trends-and-global

https://topprnews.com/demand-response-management-systems-market-size/

https://topprnews.com/electrophoresis-reagents-market-trends/

https://topprnews.com/electric-aircraft-market-growth/

Learn About Us:
The Business Research Company is a market intelligence firm that pioneers in market, company, and consumer research. TBRC’s specialist consultants are located globally and are experts in a wide range of industries that include healthcare, manufacturing, financial services, chemicals, and technology. The firm has offices located in the UK, the US, and India, along with a network of proficient researchers in 28 countries.

Contact Us:
The Business Research Company
Europe: +44 207 1930 708
Asia: +91 88972 63534
Americas: +1 315 623 0293
Email: [email protected]

Follow Us On:

LinkedIn: https://in.linkedin.com/company/the-business-research-company

Twitter: https://twitter.com/tbrc_info

Facebook: https://www.facebook.com/TheBusinessResearchCompany

YouTube: https://www.youtube.com/channel/UC24_fI0rV8cR5DxlCpgmyFQ

Blog: https://blog.tbrc.info/

Healthcare Blog: https://healthcareresearchreports.com/

Global Market Model: https://www.thebusinessresearchcompany.com/global-market-model


Spread the love

About Top PR News

TopPRnews Leads Drives Search Engine Visibility For Your Press Release Content. Our Global Network Reaches Important Contacts, Media Partners And Websites And Journalists. Happy Postings! If You Have Any Queries Please Contact Official Mail At [[email protected]}

View all posts by Top PR News →